Sign Out
Instructions for Use/Handling: Parenteral solutions should be inspected visually for particulate matter and discoloration prior to administration.
ARIXTRA is administered by subcutaneous injection or intravenous injection. It must not be administered by intramuscular injection. The subcutaneous injection is administered in the same way as with a standard syringe.
The ARIXTRA pre-filled syringe has been designed with an automatic needle protection system to prevent needle stick injuries following injection.
Instruction for self-administration by subcutaneous injection is included in the package leaflet.
Any unused product or waste material should be disposed of in accordance with local requirements.
2.5 mg/0.5 mL: Intravenous administration should be through an existing intravenous line either directly or using a small volume (25 or 50ml) 0.9% saline minibag.
Incompatibilities: In the absence of compatibility studies, ARIXTRA must not be mixed with other medicinal products.
